Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that plays a pivotal role in accelerating the development of groundbreaking therapeutic candidates. With an extensive portfolio of over 70 assets, XOMA acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotech companies. This unique model enables XOMA to provide non-dilutive, non-recourse funding to its partners, helping them advance their internal drug candidates or cater to general corporate needs.
Notably, XOMA has pioneered in the discovery and development of antibody therapeutics, leading to over 20 licenses producing milestone and royalty payments in the future. One key asset in their portfolio is X358, an allosteric monoclonal antibody aimed at treating hyperinsulinism by reducing insulin receptor activity.
XOMA has recently expanded its portfolio through strategic acquisitions. In January 2024, the company acquired an economic interest in DSUVIA® (sufentanil sublingual tablet) from Talphera, Inc., for $8 million. DSUVIA® is an FDA-approved pain management option used in supervised medical settings. The agreement stipulates that XOMA will receive all royalties and milestones related to DSUVIA® until $20 million is accrued. Subsequently, royalties will be shared between XOMA and Talphera.
Further broadening its portfolio, XOMA acquired Kinnate Biopharma in April 2024, bringing additional assets into their royalty pipeline. Kinnate’s lead candidates include investigational pan-RAF inhibitor exarafenib and FGFR inhibitor KIN-3248, both targeting cancers with specific genetic alterations.
In April 2024, XOMA announced a $9 million milestone following the FDA approval of Day One Biopharmaceuticals’ OJEMDA™ (tovorafenib), designed to treat pediatric low-grade glioma harboring BRAF alterations. This approval marks a significant addition to XOMA's cash flow and royalty income.
Additionally, XOMA's economic interest in three of Daré Bioscience's women's health products, including the FDA-approved XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream, 3.6%, signifies their commitment to addressing underrepresented therapeutic areas with significant growth potential.
As of their latest financial results, XOMA reported strong cash reserves and a growing portfolio of commercial and development-phase assets, ensuring long-term sustainability and value creation for shareholders. The company’s disciplined approach to capital deployment and strategic acquisitions highlights its commitment to enhancing human health through biotechnology advancements.
On April 26, 2023, XOMA Corporation (NASDAQ: XOMA) announced that Owen Hughes, Executive Chairman, and Brad Sitko, Chief Investment Officer, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference. This event is scheduled for May 2, 2023, at 10:30 AM ET. Investors can access the chat through a link provided or via the investor relations section of XOMA's website. A replay of the discussion will be available for 90 days post-event.
XOMA operates as a biotechnology royalty aggregator, acquiring future economic rights tied to pre-commercial therapeutic candidates. With over 70 assets in its portfolio, it provides non-dilutive funding to biotech companies. For more information, visit www.xoma.com.
FAQ
What is the current stock price of XOMA Royalty Corporation (XOMA)?
What is the market cap of XOMA Royalty Corporation (XOMA)?
What does XOMA Corporation do?
What is XOMA’s business model?
What recent acquisitions has XOMA made?
What are some key assets in XOMA's portfolio?
How does XOMA generate revenue?
What is the significance of XOMA’s investment in X358?
How does XOMA support biotech companies?
What was the financial impact of XOMA’s acquisition of DSUVIA®?
Who are some of XOMA’s partners?
What are XOMA's future plans for growth?
